We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $33.05, marking a -3.09% move from the previous day. This change lagged the S&P 500's 0.14% loss on the day. Elsewhere, the Dow lost 0.2%, while the tech-heavy Nasdaq lost 0.24%.
Prior to today's trading, shares of the company had lost 9.09% lagged the Medical sector's loss of 0.56% and the S&P 500's gain of 0.94%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. It is anticipated that the company will report an EPS of $0.04, marking a 63.64% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $620.41 million, reflecting a 28.94% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.48 per share and a revenue of $2.35 billion, representing changes of +77.78% and +59.16%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.69% rise in the Zacks Consensus EPS estimate. Hims & Hers Health, Inc. is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 70.6. This expresses a premium compared to the average Forward P/E of 47.79 of its industry.
It's also important to note that HIMS currently trades at a PEG ratio of 6.74. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 3.48.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 106, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $33.05, marking a -3.09% move from the previous day. This change lagged the S&P 500's 0.14% loss on the day. Elsewhere, the Dow lost 0.2%, while the tech-heavy Nasdaq lost 0.24%.
Prior to today's trading, shares of the company had lost 9.09% lagged the Medical sector's loss of 0.56% and the S&P 500's gain of 0.94%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. It is anticipated that the company will report an EPS of $0.04, marking a 63.64% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $620.41 million, reflecting a 28.94% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.48 per share and a revenue of $2.35 billion, representing changes of +77.78% and +59.16%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.69% rise in the Zacks Consensus EPS estimate. Hims & Hers Health, Inc. is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 70.6. This expresses a premium compared to the average Forward P/E of 47.79 of its industry.
It's also important to note that HIMS currently trades at a PEG ratio of 6.74. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 3.48.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 106, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.